These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 39250644)

  • 1. COVID-19 Breakthrough Infections Among People With HIV: A Statewide Cohort Analysis.
    Yang X; Zhang J; Chen S; Liu Z; Poland GA; Olatosi B; Weissman S; Li X
    J Acquir Immune Defic Syndr; 2024 Oct; 97(2):107-116. PubMed ID: 39250644
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Analysis of Postvaccination Breakthrough COVID-19 Infections Among Adults With HIV in the United States.
    Coburn SB; Humes E; Lang R; Stewart C; Hogan BC; Gebo KA; Napravnik S; Edwards JK; Browne LE; Park LS; Justice AC; Gordon KS; Horberg MA; Certa JM; Watson E; Jefferson CR; Silverberg MJ; Skarbinski J; Leyden WA; Williams CF; Althoff KN;
    JAMA Netw Open; 2022 Jun; 5(6):e2215934. PubMed ID: 35671054
    [TBL] [Abstract][Full Text] [Related]  

  • 3. COVID-19 infections post-vaccination by HIV status in the United States.
    Coburn SB; Humes E; Lang R; Stewart C; Hogan BC; Gebo KA; Napravnik S; Edwards JK; Browne LE; Park LS; Justice AC; Gordon K; Horberg MA; Certa JM; Watson E; Jefferson CR; Silverberg M; Skarbinski J; Leyden WA; Williams CF; Althoff KN;
    medRxiv; 2021 Dec; ():. PubMed ID: 34909791
    [TBL] [Abstract][Full Text] [Related]  

  • 4. COVID-19 breakthrough infections among people living with and without HIV: A statewide cohort analysis.
    Yang X; Zhang J; Liu Z; Chen S; Olatosi B; Poland GA; Weissman S; Li X
    Int J Infect Dis; 2024 Feb; 139():21-27. PubMed ID: 38013151
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Analysis of Severe Illness After Postvaccination COVID-19 Breakthrough Among Adults With and Without HIV in the US.
    Lang R; Humes E; Coburn SB; Horberg MA; Fathi LF; Watson E; Jefferson CR; Park LS; Gordon KS; Akgün KM; Justice AC; Napravnik S; Edwards JK; Browne LE; Agil DM; Silverberg MJ; Skarbinski J; Leyden WA; Stewart C; Hogan BC; Gebo KA; Marconi VC; Williams CF; Althoff KN;
    JAMA Netw Open; 2022 Oct; 5(10):e2236397. PubMed ID: 36227594
    [TBL] [Abstract][Full Text] [Related]  

  • 6. COVID-19 Breakthrough Infection after Vaccination and Substance Use Disorders: A Longitudinal Cohort of People with and without HIV Receiving Care in the United States Veterans Health Administration.
    Soyer EM; McGinnis KA; Justice AC; Hsieh E; Rodriguez-Barradas MC; Williams EC; Park LS
    AIDS Behav; 2024 Nov; 28(11):3605-3614. PubMed ID: 39046612
    [TBL] [Abstract][Full Text] [Related]  

  • 7. COVID-19 Testing Among People with HIV: A Population Level Analysis Based on Statewide Data in South Carolina.
    Shi F; Zhang J; Yang X; Gao H; Chen S; Weissman S; Olatosi B; Li X
    AIDS Behav; 2024 Oct; 28(Suppl 1):22-32. PubMed ID: 38109020
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Incidence of COVID-19 mRNA vaccine symptomatic breakthrough infections during Omicron circulation in adults with or without infection prior to vaccination.
    Durier C; Ninove L; van der Werf S; Lefebvre M; Desaint C; Bauer R; Attia M; Lecompte AS; Lachatre M; Maakaroun-Vermesse Z; Nicolas JF; Verdon R; Kiladjian JJ; Loubet P; Schmidt-Mutter C; Corbin V; Ansart S; Melica G; Resch M; Netzer E; Kherabi Y; Tardieu R; Lelièvre JD; Tartour E; Meyer L; de Lamballerie X; Launay O;
    Infect Dis Now; 2024 Aug; 54(5):104886. PubMed ID: 38494117
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Incidence of Severe COVID-19 Illness Following Vaccination and Booster With BNT162b2, mRNA-1273, and Ad26.COV2.S Vaccines.
    Kelly JD; Leonard S; Hoggatt KJ; Boscardin WJ; Lum EN; Moss-Vazquez TA; Andino R; Wong JK; Byers A; Bravata DM; Tien PC; Keyhani S
    JAMA; 2022 Oct; 328(14):1427-1437. PubMed ID: 36156706
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Incidence and risk factors of SARS-CoV-2 breakthrough infection in the early Omicron variant era among vaccinated and boosted individuals in Chicago.
    Moreno Echevarria F; Caputo M; Camp D; Reddy S; Achenbach CJ
    PLoS One; 2024; 19(8):e0302338. PubMed ID: 39102410
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Association Between Immune Dysfunction and COVID-19 Breakthrough Infection After SARS-CoV-2 Vaccination in the US.
    Sun J; Zheng Q; Madhira V; Olex AL; Anzalone AJ; Vinson A; Singh JA; French E; Abraham AG; Mathew J; Safdar N; Agarwal G; Fitzgerald KC; Singh N; Topaloglu U; Chute CG; Mannon RB; Kirk GD; Patel RC;
    JAMA Intern Med; 2022 Feb; 182(2):153-162. PubMed ID: 34962505
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Omicron BA.1-specific T-cell responses in adults vaccinated with CoronaVac or BNT162b2 in Hong Kong: an observational cohort study.
    Mok CKP; Chen C; Zhao S; Sun Y; Yiu K; Chan TO; Lai HL; Lai KC; Lau KM; Ling KC; Chan KKP; Ng SS; Ko FW; Peiris M; Hui DS
    Lancet Microbe; 2023 Jun; 4(6):e418-e430. PubMed ID: 37086735
    [TBL] [Abstract][Full Text] [Related]  

  • 13. T-Cell Responses to COVID-19 Vaccines and Breakthrough Infection in People Living with HIV Receiving Antiretroviral Therapy.
    Datwani S; Kalikawe R; Waterworth R; Mwimanzi FM; Liang R; Sang Y; Lapointe HR; Cheung PK; Omondi FH; Duncan MC; Barad E; Speckmaier S; Moran-Garcia N; DeMarco ML; Hedgcock M; Costiniuk CT; Hull M; Harris M; Romney MG; Montaner JSG; Brumme ZL; Brockman MA
    Viruses; 2024 Apr; 16(5):. PubMed ID: 38793543
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Breakthrough SARS-CoV-2 infections and prediction of moderate-to-severe outcomes during rituximab therapy in patients with rheumatic and musculoskeletal diseases in the UK: a single-centre cohort study.
    Md Yusof MY; Arnold J; Saleem B; Vandevelde C; Dass S; Savic S; Vital EM; Emery P
    Lancet Rheumatol; 2023 Feb; 5(2):e88-e98. PubMed ID: 36712951
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Breakthrough SARS-CoV-2 Infections, Hospitalizations, and Mortality in Vaccinated Patients With Cancer in the US Between December 2020 and November 2021.
    Wang W; Kaelber DC; Xu R; Berger NA
    JAMA Oncol; 2022 Jul; 8(7):1027-1034. PubMed ID: 35394485
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Humoral response after mRNA COVID-19 primary vaccination and single booster dose in people living with HIV compared to controls: A French nationwide multicenter cohort study-ANRS0001s COV-POPART.
    Loubet P; Lelievre JD; François A; Botelho-Nevers E; Chidiac C; Chirio D; Dubee V; Dussol B; Galtier F; Hessamfar M; Hodaj E; Jaffuel S; Lacombe K; Laine F; Lefebvre M; Maakaroun-Vermesse Z; Makinson A; Portefaix A; Pourcher V; Rey D; Zucman D; Longobardi J; Bertheau M; Tartour E; de Lamballerie X; Launay O; Wittkop L;
    Int J Infect Dis; 2024 Sep; 146():107110. PubMed ID: 38825164
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Association of a Third Dose of BNT162b2 Vaccine With Incidence of SARS-CoV-2 Infection Among Health Care Workers in Israel.
    Spitzer A; Angel Y; Marudi O; Zeltser D; Saiag E; Goldshmidt H; Goldiner I; Stark M; Halutz O; Gamzu R; Slobodkin M; Amrami N; Feigin E; Elbaz M; Furman M; Bronstein Y; Chikly A; Eshkol A; Furer V; Mayer T; Meijer S; Melloul A; Mizrahi M; Yakubovsky M; Rosenberg D; Safir A; Spitzer L; Taleb E; Elkayam O; Silberman A; Eviatar T; Elalouf O; Levinson T; Pozyuchenko K; Itzhaki-Alfia A; Sprecher E; Ben-Ami R; Henig O
    JAMA; 2022 Jan; 327(4):341-349. PubMed ID: 35006256
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of mRNA Vaccine Boosters against SARS-CoV-2 Omicron Infection in Qatar.
    Abu-Raddad LJ; Chemaitelly H; Ayoub HH; AlMukdad S; Yassine HM; Al-Khatib HA; Smatti MK; Tang P; Hasan MR; Coyle P; Al-Kanaani Z; Al-Kuwari E; Jeremijenko A; Kaleeckal AH; Latif AN; Shaik RM; Abdul-Rahim HF; Nasrallah GK; Al-Kuwari MG; Butt AA; Al-Romaihi HE; Al-Thani MH; Al-Khal A; Bertollini R
    N Engl J Med; 2022 May; 386(19):1804-1816. PubMed ID: 35263534
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Humoral and cellular immunogenicity of homologous and heterologous booster vaccination in Ad26.COV2.S-primed individuals: Comparison by breakthrough infection.
    Hyun H; Jang AY; Park H; Heo JY; Seo YB; Nham E; Yoon JG; Seong H; Noh JY; Cheong HJ; Kim WJ; Yoon SY; Seok JH; Kim J; Park MS; Song JY
    Front Immunol; 2023; 14():1131229. PubMed ID: 36960070
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Autoimmune Sequelae After Delta or Omicron Variant SARS-CoV-2 Infection in a Highly Vaccinated Cohort.
    Wee LE; Lim JT; Tay AT; Chiew CJ; Ong B; Lye DCB; Lahiri M; Tan KB
    JAMA Netw Open; 2024 Aug; 7(8):e2430983. PubMed ID: 39212988
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.